DARZALEX FASPRO

Jul 20, 2026

Summary SARCLISA ESCENA is the first anticancer treatment approved for delivery via an on-body injector — approved in the US, EU, and UK. It's delivered via CirCLIQ, a hands-free wearable device built on Enable Injections' enFuse platform. Approval was supported by the Phase 3 IRAKLIA trial, showing effic...

Sep 23, 2024

Better late than never for FDA approval of the first subcutaneous PD-L1 inhibitor—Roche’s TECENTRIQ HYBREZA—after manufacturing delays disrupted the company’s initial launch plans last year. The FDA was originally set to decide on TECENTRIQ’s under-the-skin formulation in September, but Roche’s delivery technolo...

Aug 05, 2024

Despite significant progress in multiple myeloma treatment with a range of biological drugs and their combinations—such as IMiDs (BMS REVLIMID, POMALYST/IMNOVID), anti-CD38 monoclonal antibody drugs (DARZALEX, SARCLISA), the anti-SLAM7 monoclonal antibody (AbbVie and BMS multiple myeloma drug EMPLICITI), and new pr...